TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02334800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75 mg Capsule
Description: Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75 mg Capsule
Description: Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75 mg Capsule
Description: Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75 mg Capsule
Description: Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
Study: NCT02853968

Intervention type: PROCEDURE
Intervention: Blood draw/buccal swab
Description: The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.

Intervention type: PROCEDURE
Intervention: Blood draw/buccal swab
Description: The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.

Intervention type: PROCEDURE
Intervention: Blood draw/buccal swab
Description: The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
Study: NCT02828111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT01428960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil
Description: Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil
Description: Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil
Description: Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
Study: NCT03721991

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gama amino butyric acid (GABA)
Description: food supplement Gama amino butyric acid (GABA) as capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT04317820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Brain Reorienting (DBR)
Description: Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
Study: NCT03579563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUD fitting
Description: Prescription hearing aids will be fitted by audiologists using established procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUD fitting
Description: Prescription hearing aids will be fitted by audiologists using established procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC+ fitting
Description: Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC+ fitting
Description: Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC fitting
Description: In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC fitting
Description: In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-end HA
Description: High-end hearing aids will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-end HA
Description: High-end hearing aids will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-end HA
Description: High-end hearing aids will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-end HA
Description: Low-end hearing aids will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-end HA
Description: Low-end hearing aids will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-end HA
Description: Low-end hearing aids will be used.
Study: NCT00936364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term fasting
Description: No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term fasting
Description: No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
Study: NCT02149550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135 n=2
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135 n=1
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF166 n=5
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166 n=2
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166 n=1
Description: Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
Study: NCT04583839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
Study: NCT01407575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT03746301

Intervention type: DRUG
Intervention: Rivaroxaban(Xarelto,BAY 59-7939)
Description: 10mg, 15mg and 20 mg film-coated tablets
Study: NCT00764803

Intervention type: DEVICE
Intervention: Encore 3DKnee™ system
Description: Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.

Intervention type: DEVICE
Intervention: Encore MJS™ Knee System
Description: Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
Study: NCT03124797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD DCI Sensor
Description: Noninvasive pulse oximeter sensor
Study: NCT03779594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
Study: NCT02156349

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix Software
Description: Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix readout Device
Description: Smartpix device for data upload out of blood glucose meter devices
Study: NCT03812679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMIA APD Solution Generation System
Description: The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
Study: NCT00778271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 400mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 400mg capsules
Study: NCT03372083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
Study: NCT04133090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous block bone graft
Description: Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: i-PRF enriched allograft material+ screw tent pole technique
Description: The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
Study: NCT02162511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ cell enrichment and T-cell depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ cell enrichment and T-cell depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ cell enrichment and T-cell depletion
Study: NCT03884933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile team community mental health services
Description: The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
Study: NCT04379388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web + text smoking cessation intervention
Description: Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
Study: NCT00773981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal vacuum assisted drainage
Description: Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
Study: NCT02293811

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis
Description: An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating).
Study: NCT02420899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10mg/d or 20mg/d,po
Study: NCT02908828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calanus oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo dietary oil
Study: NCT00820391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-Relaxation
Description: a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
Study: NCT03778359

Intervention type: DRUG
Intervention: Leuprorelin
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.

Intervention type: DEVICE
Intervention: Levonorgestrel
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.

Intervention type: DRUG
Intervention: Dienogest
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.

Intervention type: DRUG
Intervention: Progestins
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
Study: NCT01205529

Intervention type: DRUG
Group type: OTHER
Intervention: Procainamide
Description: One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
Study: NCT00662714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: oral; initial dose: 3x 0.5mg/d; 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short-acting Insulin (Actrapid)
Description: initial dose: 3x 0.05E/kg/d, injected; 2 years
Study: NCT04352491

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01535157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide/LXS + Ketoconazole
Description: Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
Study: NCT06079086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Implants Lifesil
Description: The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Implants Lifesil
Description: The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
Study: NCT01156181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Embryo transfer without any intervention
Study: NCT00936364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term fasting
Description: No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified fast
Description: Minimal caloric intake on days -2 and -1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Day -1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Days -2 and -1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Days -3, -2, and -1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 48-hour fast with minimal caloric intake on days -2 and -1
Study: NCT00560547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms / 4 weeks iv (starting dose)
Study: NCT04179032

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.